Newco Vitaeris licenses Alder's clazakizumab

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) granted newco Vitaeris Inc. (Vancouver, B.C.) exclusive, worldwide rights to anti-IL-6 mAb clazakizumab (formerly ALD518). Alder helped co-found Vitaeris to house clazakizumab, which the

Read the full 281 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE